30 articles for WH Miller
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
15
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.
Smithkline Beecham Pharmaceuticals
6
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
40
Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity.
Glaxosmithkline
12
Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.
Glaxosmithkline
48
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Glaxosmithkline
7
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.
Glaxosmithkline
17
Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series
TBA
2
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Johns Hopkins University
6
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Glaxosmithkline
7
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Smithkline Beecham Pharmaceuticals
5
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Smithkline Beecham Pharmaceuticals
18
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.
Smithkline Beecham Pharmaceuticals
21
Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
Smithkline Beecham Pharmaceuticals
40
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
14
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
10
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
Smithkline Beecham Pharmaceuticals
4
Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore.
Smithkline Beecham Pharmaceuticals
22
Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors.
Glaxosmithkline Research & Development
4
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Glaxosmithkline
716
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
716
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
48
Aniline derivative, pharmaceutical composition containing same, and use thereof
Kissei Pharmaceutical
6
Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
Bristol-Myers Squibb
11
Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
Amgen
70
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Glaxosmithkline
35
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Dupont Pharmaceuticals